# MagDI Diversion Feasibility Study

> **NCT05692518** · NA · COMPLETED · sponsor: **GT Metabolic Solutions, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity

## Interventions

- **DEVICE:** MAGNET System, DI Bio-fragmentable

## Key facts

- **NCT ID:** NCT05692518
- **Lead sponsor:** GT Metabolic Solutions, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-19
- **Primary completion:** 2024-08-23
- **Final completion:** 2025-05-20
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2025-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05692518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05692518, "MagDI Diversion Feasibility Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05692518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*